PharmAla Supplies LaNeo MDMA for Clinical Research
PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTC: MDXXF) announces an exciting advancement as it is contracted to provide LaNeo™ MDMA, a vital component for an ongoing clinical trial at Yale University. As a leader in the biotechnology sector, PharmAla prides itself on its dedication to the development and manufacturing of MDXX class molecules, particularly MDMA.
CEO's Insights on Clinical Trial Collaborations
In a recent statement, Nicholas Kadysh, the CEO of PharmAla, expressed the company’s enthusiasm about the growing interest in LaNeo™ MDMA for research purposes. He noted, “Requests for clinical trial material continue to occupy the Company at this time. We are happy to be well thought-of in academic circles and continue to collaborate with multiple research partners to deliver drug products for clinical trials promptly.” This collaboration not only underscores the importance of MDMA in therapeutic contexts but also suggests that PharmAla is firmly establishing itself as a reputable supplier in the academic research landscape.
Accessible Tools for Researchers
PharmAla offers researchers a dedicated tool which grants them access to crucial drug product quality data directly, enhancing the ease with which they can evaluate LaNeo MDMA for their studies. Thanks to their commitment to customer service, PharmAla ensures rapid support for converting clinical trial registrations and IRB approvals into comprehensive Chemistry, Manufacturing and Control packages for LaNeo MDMA.
Debt Settlement through Share Issuance
In addition to their supply agreement, PharmAla has recently announced a strategic move to address financial commitments. The board of directors has greenlit the settlement of $100,000 owed to arm’s length creditors through the issuance of common shares. The actual price per share will be determined at the time of settlement, showcasing the company’s proactive approach to managing its financial responsibilities while fostering its growth.
A Closer Look at PharmAla's Mission
Founded with a vision that merges the need for clinical-grade MDMA with the drive to innovate, PharmAla is committed to alleviating the global demand for generic, clinical-grade MDMA. This ambitious objective not only facilitates clinical trials but also positions PharmAla effectively for potential commercial sales across select regions.
Innovation in Research and Development
PharmAla has distinguished itself as the sole provider of clinical-grade MDMA for patient treatments outside clinical trials. Their dedicated research and development division has successfully completed proof-of-concept studies on various IP families, including its flagship drug candidate, ALA-002. With a regulatory-first approach, PharmAla operates under the ethos that forging excellent relationships with regulators is fundamental for success in the rapidly evolving psychedelics industry.
Contact Information for Queries
For any inquiries, interested parties can connect with Nicholas Kadysh, the Chief Executive Officer of PharmAla Biotech Holdings Inc. He can be reached by email at press@PharmAla.ca or via phone at 1-855-444-6362. More about the company can be found at www.PharmAla.ca.
Frequently Asked Questions
What is LaNeo MDMA?
LaNeo MDMA is a novel formulation of MDMA developed by PharmAla Biotech, specifically for research and clinical use.
Who is PharmAla Biotech Holdings Inc.?
PharmAla is a biotechnology company focusing on the development and manufacturing of MDXX class molecules like MDMA, with a commitment to clinical trials and therapeutic applications.
What are the aims of the clinical trial at Yale?
The clinical trial aims to study the effects and therapeutic potential of LaNeo MDMA in a controlled environment, aiding research into its applications in treatment.
How does PharmAla support researchers?
PharmAla provides tools and access to detailed drug product quality information and offers rapid support for clinical trial processes.
What recent financial steps has PharmAla taken?
The company is addressing its debts through the strategic issuance of shares, showing a proactive approach in managing financial commitments.
